Apellis holder plans sale of 873 restricted shares

Apellis Pharmaceuticals shareholder files notice to sell restricted stock.

Rhea-AI Filing Summary

Apellis Pharmaceuticals shareholder files notice to sell restricted stock. A holder of Apellis common shares filed a Form 144 to potentially sell 873 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with the shares listed on NASDAQ. The shares have an aggregate market value of $19,369.43, compared with 126,525,218 common shares outstanding. These securities were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/12/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Apellis Pharmaceuticals (APLS) Form 144 filing report?

The Form 144 reports that a holder of 873 Apellis common shares intends to sell those shares on or about 01/13/2026 through Fidelity Brokerage Services LLC on NASDAQ.

How many Apellis (APLS) shares are covered by this Form 144?

The notice covers a proposed sale of 873 shares of Apellis common stock, with an aggregate market value of $19,369.43 as stated in the filing.

How were the Apellis (APLS) shares being sold under Form 144 acquired?

The 873 shares were acquired on 01/12/2026 through restricted stock vesting from the issuer, with the consideration described as compensation.

How does the Form 144 share amount compare to Apellis shares outstanding?

The Form 144 covers 873 shares relative to 126,525,218 Apellis common shares outstanding as reported in the document.

Which broker is handling the proposed Apellis (APLS) Form 144 sale?

The proposed sale is listed with Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, and the shares are to be sold on NASDAQ.

What representation does the seller make in the Apellis (APLS) Form 144?

The seller represents that they do not know any material adverse information about Apellis's current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 03:58 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001836430
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Apellis Pharmaceuticals, Inc.
SEC File Number	001-38276
Address of Issuer	100 FIFTH AVENUE WALTHAM MASSACHUSETTS 02451
Phone	617-977-5700
Name of Person for Whose Account the Securities are To Be Sold	Chopas James George
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	873	19369.43	126525218	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	Restricted Stock Vesting	Issuer			873	01/12/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James G. Chopas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)